NORTH-AMERICAN (UNITED-STATES AND CANADA) COMPARATIVE SUSCEPTIBILITY OF 2 FLUOROQUINOLONES - OFLOXACIN AND CIPROFLOXACIN - A 53-MEDICAL-CENTER SAMPLE OF SPECTRA OF ACTIVITY

被引:18
作者
JONES, RN
HOBAN, DJ
ALDRIDGE, KA
ARRINGTON, KL
BERTHOLD, G
BRECHER, S
CLEARY, T
COYLE, M
DAVIS, J
GARAGUSI, V
GOODMAN, NL
GORZYNSKI, E
HANFF, P
HANNA, B
ISENBERG, HD
MCGOWAN, J
MARTIN, WJ
MOODY, J
MURRAY, PR
RELLER, LB
RINALDI, MG
ROSATI, LA
RYPKA, E
SAHM, D
SLIFKIN, M
SEWELL, D
SPIEGEL, C
STECKELBERG, JM
STEELEMOORE, L
STEIN, G
STRATTON, C
STROZEWSKI, K
WEINSTEIN, M
WELCH, B
WHITE, RL
WINN, W
ALFA, M
NUNS, G
BLONDEAU, J
BOURGAULT, AM
BRUNTON, J
CLARKE, AM
FORWARD, K
GREGSON, DB
HORSMAN, GB
JESSAMINE, P
KIBSEY, P
KUHN, M
LAVERDIERE, M
LOW, DE
机构
[1] UNIV MANITOBA,HLTH SCI CTR,DEPT MED MICROBIOL & CLIN MICROBIOL,WINNIPEG,MB,CANADA
[2] LOUISIANA STATE UNIV,SCH MED,NEW ORLEANS,LA
[3] DOCTORS HOSP,TULSA,OK
[4] METHODIST HOSP,OMAHA,NE
[5] VET ADM MED CTR,BOSTON,MA
[6] JACKSON MEM HOSP,MIAMI,FL
[7] HARBORVIEW MED CTR,SEATTLE,WA
[8] METHODIST HOSP,HOUSTON,TX
[9] GEORGETOWN UNIV HOSP,WASHINGTON,DC
[10] UNIV KENTUCKY,COLL MED,LEXINGTON,KY
[11] VET ADM MED CTR,BUFFALO,NY
[12] BETH ISRAEL HOSP,BOSTON,MA
[13] NYU,MED CTR,NEW YORK,NY
[14] LONG ISL JEWISH MED CTR,NEW HYDE PK,NY
[15] GRADY MEM HOSP,ATLANTA,GA
[16] ASSOCIATED CLIN LABS,ERIE,PA
[17] ST PAUL RAMSEY HOSP,ST PAUL,MN
[18] WASHINGTON UNIV,SCH MED,ST LOUIS,MO
[19] DUKE UNIV,MED CTR,DURHAM,NC
[20] UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX
[21] SONORA LAB SCI,MESA,AZ
[22] LOVELACE HOSP,ALBUQUERQUE,NM
[23] UNIV CHICAGO,CHICAGO,IL
[24] ALLEGHENY GEN HOSP,PITTSBURGH,PA
[25] VET ADM MED CTR,PORTLAND,OR
[26] UNIV WISCONSIN HOSP,MADISON,WI
[27] MAYO CLIN & MAYO FDN,ROCHESTER,MN
[28] MED CTR DELAWARE,WILMINGTON,DE
[29] MICHIGAN STATE UNIV,E LANSING,MI
[30] VANDERBILT UNIV SCH MED,NASHVILLE,TN
[31] ST VINCENTS MED CTR,CLEVELAND,OH
[32] ROBERT WOOD JOHNSON MED CTR,NEW BRUNSWICK,NJ
[33] KAISER PERMANENTE MED CTR,SAN DIEGO,CA
[34] KAISER PERMANENTE MED CTR,LOS ANGELES,CA
[35] MED UNIV S CAROLINA,CHARLESTON,SC
[36] MED CTR VERMONT,BURLINGTON,VT
[37] ST BONIFACE GEN HOSP,WINNIPEG,MB,CANADA
[38] ST PAULS HOSP,SASKATOON,SK,CANADA
[39] HOSP ST LUC,MONTREAL,PQ,CANADA
[40] TORONTO HOSP,TORONTO,ON,CANADA
[41] ST PAULS HOSP,VANCOUVER,BC,CANADA
[42] VICTORIA GEN HOSP,HALIFAX,NS,CANADA
[43] ST JOSEPHS HLTH CTR,LONDON,ON,CANADA
[44] HE ROBERTSON LAB,REGINA,SK,CANADA
[45] OTTAWA CIVIC HOSP,OTTAWA,ON,CANADA
[46] UNIV ALBERTA HOSP,EDMONTON,AB,CANADA
[47] MONCTON HOSP,MONCTON,NB,CANADA
[48] HOSP MAISONNEUVE ROSEMONT,MONTREAL,PQ,CANADA
[49] MT SINAI HOSP,TORONTO,ON,CANADA
[50] PEEL MEM HOSP,TORONTO,ON,CANADA
关键词
D O I
10.1016/0732-8893(94)90133-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Ofloxacin, a newer broad-spectrum fluoroquinolone, was evaluated against > 12,000 clinical isolates in a multicenter surveillance trial in the United States and Canada using the standardized disk diffusion method. A total of 53 geographically diverse clinical microbiology laboratories contributed zone diameter results for ofloxacin, ciprofloxacin, and norfloxacin for urinary tract infection (UTI) isolates; and ofloxacin and ciprofloxacin for respiratory tract infection (RTI) isolates, skin and soft tissue infection (SSTI) isolates, and genital tract pathogen isolates. In both the USA and Canada, ofloxacin was shown to have the wide spectrum of activity as follows: RTI isolates, ofloxacin (92.2%-93.8% susceptible), ciprofloxacin (89.5%-90.4%); SSTI isolates, ofloxacin (87.1%-93.6%) > ciprofloxacin (78.8%-90.4%); UTI isolates, ofloxacin (91.6%-92.5%) > norfloxacin (87.3%-91.7%) > ciprofloxacin (86.4%-89.7%); and genital tract isolates, ofloxacin (94.0%) > ciprofloxacin (85.4%) (Canada only). US strains resistant to ofloxacin were confirmed by reference laboratory tests. Confirmed ofloxacin resistance, other than among staphylococci or nonenteric bacilli, was rare. The species most often found to be resistant to both ofloxacin and ciprofloxacin were methicillin-resistant staphylococci, Acinetobacter spp., and Enterococcus spp. From these contributing US and Canadian laboratory studies, ofloxacin appears to have a balanced spectrum of potential clinical use (91.8% susceptible aerobic isolates), particularly against Gram-positive pathogens and some species resistant to ciprofloxacin. The combined overall isolate (12,241 isolates) rates of susceptibility for ciprofloxacin (four infection sites) and norfloxacin (UTI only) were 87.3% and 88.8%, respectively. Monitoring for increasing fluoroquinolone resistance should be considered, however, as greater use of drugs in this class develops.
引用
收藏
页码:49 / 56
页数:8
相关论文
共 27 条